OPHLY News and Press, Ono Pharmaceutical Co Ltd ADR From 02/16/23

Summary It’s among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie. Several drugmakers are expected to begin offering biosimilar ver...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ra2 studio/Shutterstock Shares of Fate Therapeutics (NASDAQ: FATE ) stock are up 3% following a massive purchase by two of Cathie Wood’s exchange-traded funds (ETFs). Fate is a clinical stage biotec...

Ono Pharmaceutical press release ( OTCPK:OPHLF ): Q1 GAAP EPS of ¥60.36. Revenue of ¥106.72B (+22.2% Y/Y). For further details see: Ono Pharmaceutical GAAP EPS of ¥60.36, revenue of ¥106.72B

The subsector with the best value and quality scores is pharmaceutical/biotechnology. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For February

The following slide deck was published by Ono Pharmaceutical Co., Ltd. in conjunction with their 2022 Q1 earnings call. For further details see: Ono Pharmaceutical Co., Ltd. 2022 Q1 - Results - Earnings Call Presentation

Ono Pharmaceutical (OTC:OPHLF): Q1 GAAP EPS of ¥48.22. Revenue of ¥87.36B (+16.6% Y/Y). Press Release For further details see: Ono Pharmaceutical reports Q1 results